Bedrijfsoverzicht
Profusa, Inc. is a healthcare entity focused on the development of bioengineered sensors designed for the human body to detect and continuously transmit clinical-grade data for both personal and medical applications within the United States. The company operates specifically within the healthcare sector, more precisely in the medical devices industry, which implies a focus on tangible solutions for monitoring patient health conditions such as peripheral artery disease, chronic wounds, and reconstructive surgery. The current market capitalization of Profusa, Inc. stands at $1.18M, while the annual revenue for the trailing twelve months is recorded as $0, and the employee count is listed as N/A. These financial figures indicate that the company operates on a very small scale relative to established industry peers, suggesting it is likely in an early-stage development phase or a niche market position where revenue generation has not yet materialized despite the presence of specific product offerings like the Lumee Oxygen Platform. The absence of reported revenue and a market cap under $2 million typically characterizes micro-cap or pre-revenue companies that are prioritizing research and development expenditures over commercial sales expansion.
Financiële gezondheid
For the trailing twelve months, the company reported a revenue of $0 and a net income of $-29,508,000, with EBITDA figures not available for reporting. The significant gap between the zero revenue and the substantial negative net income reveals a cost structure dominated by high operating expenses, likely driven by research and development costs for bioengineered sensors rather than cost of goods sold from active sales. The free cash flow stands at $-10,704,875, which indicates that the company is burning cash at a rapid rate and possesses limited financial flexibility to fund operations without external financing or capital injection. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that mathematically occurs when revenue is zero and indicates that the company has not yet achieved profitability or covered its variable costs through sales. The balance sheet shows a cash position of $3.01M against total debt of $21.07M, meaning the company is significantly leveraged with liabilities exceeding its liquid assets. While the debt-to-equity ratio is not available, the current ratio is 0.18, a figure well below the standard threshold of 1.0, indicating severe short-term liquidity constraints where current liabilities vastly exceed current assets. Return on Equity is N/A due to the lack of positive earnings, while the return on assets is -465.1%, a metric that reveals management is currently destroying asset value relative to the capital base rather than generating returns.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E are both N/A, reflecting the company's lack of earnings which makes traditional earnings-based valuation multiples impossible to calculate or compare against industry benchmarks. The price-to-book ratio is -0.01, a negative figure that indicates the market values the company below its book value, often seen in distressed or pre-revenue entities where intangible assets and future potential are not yet reflected in historical accounting records. The price-to-sales ratio is inf (infinity), which suggests that since revenue is zero, any stock price theoretically results in an infinite multiple, rendering this metric ineffective for traditional valuation but highlighting the high risk premium associated with zero sales. The 52-week high is $412.50 and the 52-week low is $0.41, placing the current market price in a highly volatile range where the stock trades significantly below its yearly peak, illustrating the speculative nature of the investment. The beta value is 0.26, which is substantially lower than the market average of 1.0, indicating that the stock's price volatility is theoretically lower than the broader market, though this low beta in the context of negative earnings and high debt suggests a different risk profile driven by solvency concerns rather than systematic market correlation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company has not yet generated positive revenue streams to establish a growth trajectory or calculate percentage increases. Consequently, the company is not a dividend payer; the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all available capital for operations or reinvestment rather than distributing income to shareholders. Since the company is not generating positive earnings, the payout ratio is not sustainable in a traditional sense, and the firm reinvests its limited resources, primarily its $3.01M cash reserve, into developing its bioengineered sensor technology rather than paying dividends. The overall growth and income profile of Profusa, Inc. is characterized by a complete absence of historical growth metrics and dividend income, presenting a high-risk scenario where returns are entirely dependent on future successful commercialization of its medical device products.